New insight into P-Glycoprotein as a drug target

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 1, 2013, Pages 159-170

  Breier, Albert ^a   Gibalova, Lenka ^a   Seres, Mario ^a   Barancik, Miroslav ^b   Sulova, Zdenka ^a  

^a INSTITUTE OF MOLECULAR PHYSIOLOGY AND GENETICS   (Slovakia)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Apoptosis; Multidrug resistance; P glycoprotein; Protein glycosylation; Protein kinases

Indexed keywords

ANTINEOPLASTIC AGENT; APICIDIN; AZIDOPINE; CASPASE 3; CELL NUCLEUS RECEPTOR; CISPLATIN; CONCANAVALIN A; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEOXYGLUCOSE; DOCETAXEL; DOXORUBICIN; FLUTAMIDE; IFOSFAMIDE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PREGNANE X RECEPTOR; PROTEASOME; PROTEIN; PROTEIN P53; TAMOXIFEN; THAPSIGARGIN; TUNICAMYCIN; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE; ZNRD1 PROTEIN;

APOPTOSIS; CANCER GROWTH; CELL CYCLE REGULATION; CELL STRESS; CELL SURVIVAL; DNA DAMAGE; GLYCOSYLATION; HUMAN; MITOCHONDRIAL MEMBRANE; NEOPLASM; PHOSPHORYLATION; PROTEIN EXPRESSION; QUALITY CONTROL; REVIEW;

EID: 84877911075     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152013804487380     Document Type: Review

References (218)

1. Baguley, B.C. Multidrug resistance in cancer, Methods Mol. Biol., 2010, 596, pp. 1-14.
2. Lage, H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol. Life Sci., 2008, 65(20), 3145-3167.
3. Thomas, H.; Coley, H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting pglycoprotein. Cancer Control, 2003, 10(2), 159-165.
4. Breier, A.; Barancik, M.; Sulova, Z.; Uhrik, B. P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy. Curr. Cancer Drug Targets, 2005, 5(6), 457-468.
5. Glavinas, H.; Krajcsi, P.; Cserepes, J.; Sarkadi, B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr. Drug Deliv, 2004, 1(1), 27-42.
6. Mast, N.; Norcross, R.; Andersson, U.; Shou, M.; Nakayama, K.; Bjorkhem, I.; Pikuleva, I.A. Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry, 2003, 42(48), 14284-14292.
7. Park, H.; Lee, S.; Suh, J. Structural and dynamical basis of broad substrate specificity, catalytic mechanism, and inhibition of cytochrome P450 3A4. J. Am. Chem. Soc., 2005, 127(39), 13634-13642.
8. Gate, L.; Tew, K.D. Glutathione S-transferases as emerging therapeutic targets. Expert Opin Ther Targets, 2001, 5(4), 477-489.
9. Depeille, P.; Cuq, P.; Mary, S.; Passagne, I.; Evrard, A.; Cupissol, D.; Vian, L. Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects. Mol. Pharmacol., 2004, 65(4), 897-905.
10. Meijerman, I.; Beijnen, J.H.; Schellens, J.H. Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. Cancer Treat Rev., 2008, 34(6), 505-520.
11. Christians, U.; Schmitz, V.; Haschke, M. Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin. Drug Metab. Toxicol., 2005, 1(4), 641-654.
12. Mudra, D.R.; Desino, K.E.; Desai, P.V. In silico, in vitro and in situ models to assess interplay between CYP3A and P-gp. Curr. Drug Metab., 2011, 12(8), 750-773.
13. van Waterschoot, R.A.; Schinkel, A.H. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice. Pharmacol. Rev., 2011, 63(2), 390-410.
14. Juliano, R.L.; Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 1976, 455(1), 152-162.
15. Hamada, H.; Tsuruo, T. Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res., 1988, 48(17), 4926-4932.
16. Horio, M.; Gottesman, M.M.; Pastan, I. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc. Natl. Acad. Sci. U. S. A., 1988, 85(10), 3580-3584.
17. Naito, M.; Hamada, H.; Tsuruo, T. ATP/Mg2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells. J. Biol. Chem., 1988, 263(24), 11887-11891.
18. Grandjean-Forestier, F.; Stenger, C.; Robert, J.; Verdier, M.; Ratinaud, M.-H., The p-glycoprotein 170: just a multidrug resistance protein or a protean molecule?, ABC Transporters and Multidrug Resistance, A. Boumendjel, J. Boutonnat, J. Robert (Eds.) John Wiley & Sons, Inc., 2009, pp. 18-46.
19. Fromm, M.F. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci., 2004, 25(8), 423-429.
20. Lum, B.L.; Gosland, M.P. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol. Oncol. Clin. North Am., 1995, 9(2), 319-336.
21. Pavek, P.; Fendrich, Z.; Staud, F. [Physiologic function of Pglycoprotein]. Cesk Fysiol, 2002, 51(3), 99-107.
22. Sugawara, I. Expression and functions of P-glycoprotein (mdr1 gene product) in normal and malignant tissues. Acta Pathol. Jpn., 1990, 40(8), 545-553.
23. Kvackajova-Kisucka, J.; Barancik, M.; Breier, A. Drug transporters and their role in multidrug resistance of neoplastic cells. Gen. Physiol. Biophys., 2001, 20(3), 215-237.
24. Dean, M.; Hamon, Y.; Chimini, G. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res., 2001, 42(7), 1007-1017.
25. Dean, M.; Rzhetsky, A.; Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res., 2001, 11(7), 1156-1166.
26. Hyde, S.C.; Emsley, P.; Hartshorn, M.J.; Mimmack, M.M.; Gileadi, U.; Pearce, S.R.; Gallagher, M.P.; Gill, D.R.; Hubbard, R.E.; Higgins, C.F. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature, 1990, 346(6282), 362-365.
27. Gribar, J.J.; Ramachandra, M.; Hrycyna, C.A.; Dey, S.; Ambudkar, S.V. Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system. J. Membr. Biol., 2000, 173(3), 203-214.
28. Orr, G.A.; Han, E.K.; Browne, P.C.; Nieves, E.; O'Connor, B.M.; Yang, C.P.; Horwitz, S.B. Identification of the major phosphorylation domain of murine mdr1b P-glycoprotein. Analysis of the protein kinase A and protein kinase C phosphorylation sites. J. Biol. Chem., 1993, 268(33), 25054-25062.
29. Hafkemeyer, P.; Dey, S.; Ambudkar, S.V.; Hrycyna, C.A.; Pastan, I.; Gottesman, M.M. Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein. Biochemistry, 1998, 37(46), 16400-16409.
30. Kajiji, S.; Talbot, F.; Grizzuti, K.; Van Dyke-Phillips, V.; Agresti, M.; Safa, A.R.; Gros, P. Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain 11 as a putative drug binding site. Biochemistry, 1993, 32(16), 4185-4194.
31. Loo, T.W.; Clarke, D.M. Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. Biochemistry, 1994, 33(47), 14049-14057.
32. Loo, T.W.; Clarke, D.M. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J. Membr. Biol., 2005, 206(3), 173-185.
33. Taguchi, Y.; Kino, K.; Morishima, M.; Komano, T.; Kane, S.E.; Ueda, K. Alteration of substrate specificity by mutations at the His61 position in predicted transmembrane domain 1 of human MDR1/P-glycoprotein. Biochemistry, 1997, 36(29), 8883-8889.
34. Loo, T.W.; Clarke, D.M. Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteinescanning mutagenesis and thiol-modification techniques. Biochim. Biophys. Acta, 1999, 1461(2), 315-325.
35. Loo, T.W.; Bartlett, M.C.; Clarke, D.M. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding. J. Biol. Chem., 2003, 278(16), 13603-13606.
36. Wang, R.B.; Kuo, C.L.; Lien, L.L.; Lien, E.J. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin. Pharm. Ther., 2003, 28(3), 203-228.
37. Breier, A.; Drobna, Z.; Docolomansky, P.; Barancik, M. Cytotoxic activity of several unrelated drugs on L1210 mouse leukemic cell sublines with P-glycoprotein (PGP) mediated multidrug resistance (MDR) phenotype. A QSAR study. Neoplasma, 2000, 47(2), 100-106.
38. Bohacova, V.; Sulova, Z.; Dovinova, I.; Polakova, E.; Barancik, M.; Uhrik, B.; Orlicky, J.; Breier, A. L1210 cells cultivated under the selection pressure of doxorubicin or vincristine express common mechanisms of multidrug resistance based on the overexpression of P-glycoprotein. Toxicol In Vitro, 2006, 20(8), 1560-1568.
39. Harmsen, S.; Meijerman, I.; Febus, C.L.; Maas-Bakker, R.F.; Beijnen, J.H.; Schellens, J.H. PXR-mediated induction of Pglycoprotein by anticancer drugs in a human colon adenocarcinomaderived cell line. Cancer Chemother. Pharmacol., 2010, 66(4), 765-771.
40. Kim, Y.K.; Kim, N.H.; Hwang, J.W.; Song, Y.J.; Park, Y.S.; Seo, D.W.; Lee, H.Y.; Choi, W.S.; Han, J.W.; Kim, S.N. Histone deacetylase inhibitor apicidin-mediated drug resistance: involvement of P-glycoprotein. Biochem. Biophys. Res. Commun., 2008, 368(4), 959-964.
41. Polekova, L.; Barancik, M.; Mrazova, T.; Pirker, R.; Wallner, J.; Sulova, Z.; Breier, A. Adaptation of mouse leukemia cells L1210 to vincristine. Evidence for expression of P-glycoprotein. Neoplasma, 1992, 39(2), 73-77.
42. Robertson, S.J.; Kania, K.D.; Hladky, S.B.; Barrand, M.A. Pglycoprotein expression in immortalised rat brain endothelial cells: comparisons following exogenously applied hydrogen peroxide and after hypoxia-reoxygenation. J. Neurochem, 2009, 111(1), 132-141.
43. Lu, Y.; Pang, T.; Wang, J.; Xiong, D.; Ma, L.; Li, B.; Li, Q.; Wakabayashi, S. Down-regulation of P-glycoprotein expression by sustained intracellular acidification in K562/Dox cells. Biochem. Biophys. Res. Commun., 2008, 377(2), 441-446.
44. Mani, S.; Huang, H.; Sundarababu, S.; Liu, W.; Kalpana, G.; Smith, A.B.; Horwitz, S.B. Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubulestabilizing agents. Clin. Cancer Res., 2005, 11(17), 6359-6369.
45. Zhou, C.; Verma, S.; Blumberg, B. The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nucl. Recept Signal, 2009, 7(e001),
46. Cerveny, L.; Svecova, L.; Anzenbacherova, E.; Vrzal, R.; Staud, F.; Dvorak, Z.; Ulrichova, J.; Anzenbacher, P.; Pavek, P. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab. Dispos., 2007, 35(7), 1032-1041.
47. Chan, G.N.; Hoque, M.T.; Cummins, C.L.; Bendayan, R. Regulation of P-glycoprotein by orphan nuclear receptors in human brain microvessel endothelial cells. J. Neurochem., 2011, 118(2), 163-175.
48. Kliewer, S.A.; Goodwin, B.; Willson, T.M. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev., 2002, 23(5), 687-702.
49. Saeki, M.; Kurose, K.; Hasegawa, R.; Tohkin, M. Functional analysis of genetic variations in the 5'-flanking region of the human MDR1 gene. Mol. Genet. Metab., 2011, 102(1), 91-98.
50. Jones, S.A.; Moore, L.B.; Shenk, J.L.; Wisely, G.B.; Hamilton, G.A.; McKee, D.D.; Tomkinson, N.C.; LeCluyse, E.L.; Lambert, M.H.; Willson, T.M.; Kliewer, S.A.; Moore, J.T. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol., 2000, 14(1), 27-39.
51. Wandel, C.; Kim, R.B.; Kajiji, S.; Guengerich, P.; Wilkinson, G.R.; Wood, A.J. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res., 1999, 59(16), 3944-3948.
52. Zhou, S.F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab., 2008, 9(4), 310-322.
53. Demeule, M.; Brossard, M.; Beliveau, R. Cisplatin induces renal expression of P-glycoprotein and canalicular multispecific organic anion transporter. Am. J. Physiol., 1999, 277(6 Pt 2), F832-840.
54. Hamaguchi, K.; Godwin, A.K.; Yakushiji, M.; O'Dwyer, P.J.; Ozols, R.F.; Hamilton, T.C. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res., 1993, 53(21), 5225-5232.
55. Yang, X.; Page, M. P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Oncol. Res., 1995, 7(12), 619-624.
56. Masuyama, H.; Nakatsukasa, H.; Takamoto, N.; Hiramatsu, Y. Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells. Mol, Pharmacol., 2007, 72(4), 1045-1053.
57. Takami, N.; Sakamoto, H.; Yamamoto, T. Steroid and xenobiotic receptor (SXR) is a key system for the acquisition of cisplatin resistance in endometrial cancer cells. J. Int. Med. Res., 2003, 31(2), 59-68.
58. Takeshita, A.; Shinjo, K.; Naito, K.; Ohnishi, K.; Sugimoto, Y.; Yamakawa, Y.; Tanimoto, M.; Kitamura, K.; Naoe, T.; Ohno, R. Role of P-glycoprotein in all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukaemia cells: analysis of intracellular concentration of ATRA. Br. J. Haematol., 2000, 108(1), 90-92.
59. Sulova, Z.; Macejova, D.; Seres, M.; Sedlak, J.; Brtko, J.; Breier, A. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of Pglycoprotein expression and transport activity. Toxicol. In Vitro, 2008, 22(1), 96-105.
60. Ray, W.J.; Bain, G.; Yao, M.; Gottlieb, D.I. CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family. J. Biol. Chem., 1997, 272(30), 18702-18708.
61. Wang, T.; Ma, X.; Krausz, K.W.; Idle, J.R.; Gonzalez, F.J. Role of pregnane X receptor in control of all-trans retinoic acid (ATRA) metabolism and its potential contribution to ATRA resistance. J. Pharmacol. Exp. Ther., 2008, 324(2), 674-684.
62. Chen, Q.; Zhou, J.; Jiang, C.; Chen, J. Reversal of P-glycoproteinmediated multidrug resistance in SGC7901/VCR cells by PPARgamma activation by troglitazone. J. Huazhong Univ. Sci. Technolog. Med. Sci., 2010, 30(3), 326-331.
63. Brtko, J.; Thalhamer, J. Renaissance of the biologically active vitamin A derivatives: established and novel directed therapies for cancer and chemoprevention. Curr. Pharm. Des., 2003, 9(25), 2067-2077.
64. Jpenberg, A.I.; Tan, N.S.; Gelman, L.; Kersten, S.; Seydoux, J.; Xu, J.; Metzger, D.; Canaple, L.; Chambon, P.; Wahli, W.; Desvergne, B. In vivo activation of PPAR target genes by RXR homodimers. EMBO J., 2004, 23(10), 2083-2091.
65. Sulova, Z.; Brtko, J.; Macejova, D.; Breier, A., Are Nuclear Receptors for Retinoids Involved in the Control of the Expression and Activity of P-Glycoprotein?, Retinoic Acid: Structure, Mechanisms and Roles in Disease, L.-H. Cheng, Y. It (Eds.) NOVA Publisher, 2012 pp. 29-52.
66. Hong, L.; Chen, Z.; Zhang, X.; Xia, L.; Han, Z.; Lu, Y.; Jin, H.; Song, J.; Qiao, T.; Fan, D. Zinc ribbon domain containing 1 protein: modulator of multidrug resistance, tumorigenesis and cell cycle. Exp. Oncol., 2006, 28(4), 258-262.
67. Campos, L.; Oriol, P.; Sabido, O.; Guyotat, D. Simultaneous expression of P-glycoprotein and BCL-2 in acute myeloid leukemia blast cells. Leuk. Lymphoma., 1997, 27(1-2), 119-125.
68. Del Principe, M.I.; Del Poeta, G.; Maurillo, L.; Buccisano, F.; Venditti, A.; Tamburini, A.; Bruno, A.; Cox, M.C.; Suppo, G.; Tendas, A.; Gianni, L.; Postorino, M.; Masi, M.; Del Principe, D.; Amadori, S. P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia. Br. J. Haematol., 2003, 121(5), 730-738.
69. Hong, L.; Ning, X.; Shi, Y.; Shen, H.; Zhang, Y.; Lan, M.; Liang, S.; Wang, J.; Fan, D. Reversal of multidrug resistance of gastric cancer cells by down-regulation of ZNRD1 with ZNRD1 siRNA. Br. J. Biomed. Sci., 2004, 61(4), 206-210.
70. Baldwin, A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. Invest., 2001, 107(3), 241-246.
71. Bentires-Alj, M.; Barbu, V.; Fillet, M.; Chariot, A.; Relic, B.; Jacobs, N.; Gielen, J.; Merville, M.P.; Bours, V. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene, 2003, 22(1), 90-97.
72. Thevenod, F.; Friedmann, J.M.; Katsen, A.D.; Hauser, I.A. Upregulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium-and reactive oxygen species-induced apoptosis. J. Biol. Chem., 2000, 275(3), 1887-1896.
73. Guo-Chang, F.; Chu-Tse, W. Transfer of p14ARF gene in drugresistant human breast cancer MCF-7/Adr cells inhibits proliferation and reduces doxorubicin resistance. Cancer Lett., 2000, 158(2), 203-210.
74. Greer, D.A.; Ivey, S. Distinct N-glycan glycosylation of Pglycoprotein isolated from the human uterine sarcoma cell line MES-SA/Dx5. Biochim. Biophys. Acta, 2007, 1770(9), 1275-1282.
75. Loo, T.W.; Bartlett, M.C.; Clarke, D.M. Thapsigargin or curcumin does not promote maturation of processing mutants of the ABC transporters, CFTR, and P-glycoprotein. Biochem. Biophys. Res. Commun., 2004, 325(2), 580-585.
76. Schinkel, A.H.; Kemp, S.; Dolle, M.; Rudenko, G.; Wagenaar, E. N-glycosylation and deletion mutants of the human MDR1 Pglycoprotein. J. Biol. Chem., 1993, 268(10), 7474-7481.
77. Seres, M.; Cholujova, D.; Bubencikova, T.; Breier, A.; Sulova, Z. Tunicamycin depresses P-glycoprotein glycosylation without an effect on its membrane localization and drug efflux activity in L1210 Cells. Int. J. Mol. Sci., 2011, 12(11), 7772-7784.
78. Loo, T.W.; Clarke, D.M. Quality control by proteases in the endoplasmic reticulum. Removal of a protease-sensitive site enhances expression of human P-glycoprotein. J. Biol. Chem., 1998, 273(49), 32373-32376.
79. Bretthauer, R.K. Structure, expression, and regulation of UDPGlcNAc: dolichol phosphate GlcNAc-1-phosphate transferase (DPAGT1). Curr. Drug Targets, 2009, 10(6), 477-482.
80. Hiss, D.C.; Gabriels, G.A.; Folb, P.I. Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells. Cancer Cell Int, 2007, 7(5).
81. Zhang, Z.; Wu, J.Y.; Hait, W.N.; Yang, J.M. Regulation of the stability of P-glycoprotein by ubiquitination. Mol. Pharmacol., 2004, 66(3), 395-403.
82. Bentley, J.; Quinn, D.M.; Pitman, R.S.; Warr, J.R.; Kellett, G.L. The human KB multidrug-resistant cell line KB-C1 is hypersensitive to inhibitors of glycosylation. Cancer Lett., 1997, 115(2), 221-227.
83. Ledoux, S.; Yang, R.; Friedlander, G.; Laouari, D. Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res., 2003, 63(21), 7284-7290.
84. Gaddameedhi, S.; Chatterjee, S. Association between the unfolded protein response, induced by 2-deoxyglucose, and hypersensitivity to cisplatin: a mechanistic study employing molecular genomics. J Cancer Res Ther, 2009, 5 Suppl 1(S61-S66).
85. Werno, C.; Zhou, J.; Brune, B. A23187, ionomycin and thapsigargin upregulate mRNA of HIF-1alpha via endoplasmic reticulum stress rather than a rise in intracellular calcium. J. Cell. Physiol., 2008, 215(3), 708-714.
86. Seres, M.; Ditte, P.; Breier, A.; Sulova, Z. Effect of thapsigargin on P-glycoprotein-negative and P-glycoprotein-positive L1210 mouse leukaemia cells. Gen. Physiol. Biophys., 2010, 29(4), 396-401.
87. Morin, M.J.; Porter, C.W.; McKernan, P.; Bernacki, R.J. The biochemical and ultrastructural effects of tunicamycin and Dglucosamine in L1210 leukemic cells. J. Cell. Physiol., 1983, 114(2), 162-172.
88. Fiala, R.; Sulova, Z.; El-Saggan, A.H.; Uhrik, B.; Liptaj, T.; Dovinova, I.; Hanusovska, E.; Drobna, Z.; Barancik, M.; Breier, A. P-glycoprotein-mediated multidrug resistance phenotype of L1210/VCR cells is associated with decreases of oligo-and/or polysaccharide contents. Biochim. Biophys. Acta, 2003, 1639(3), 213-224.
89. Sulova, Z.; Ditte, P.; Kurucova, T.; Polakova, E.; Rogozanova, K.; Gibalova, L.; Seres, M.; Skvarkova, L.; Sedlak, J.; Pastorek, J.; Breier, A. The presence of P-glycoprotein in L1210 cells directly induces down-regulation of cell surface saccharide targets of concanavalin A. Anticancer Res., 2010, 30(9), 3661-3668.
90. Sulova, Z.; Mislovicova, D.; Gibalova, L.; Vajcnerova, Z.; Polakova, E.; Uhrik, B.; Tylkova, L.; Kovarova, A.; Sedlak, J.; Breier, A. Vincristine-induced overexpression of P-glycoprotein in L1210 cells is associated with remodeling of cell surface saccharides. J. Proteome Res., 2009, 8(2), 513-520.
91. Parfett, C.L.; Jamieson, J.C.; Wright, J.A. Changes in cell surface glycoproteins on non-differentiating L6 rat myoblasts selected for resistance to concanavalin A. Exp. Cell. Res., 1983, 144(2), 405-415.
92. Parfett, C.L.; Jamieson, J.C.; Wright, J.A. A correlation between loss of fusion potential and defective formation of mannose-linked lipid intermediates in independent concanavalin A-resistant myoblast cell lines. Exp. Cell. Res., 1981, 136(1), 1-14.
93. Gervasoni, J.E., Jr.; Taub, R.N.; Rosado, M.; Krishna, S.; Stewart, V.J.; Knowles, D.M.; Bhalla, K.; Ross, D.D.; Baker, M.A.; Lutzky, J. et al. Membrane glycoprotein changes associated with anthracycline resistance in HL-60 cells. Cancer Chemother. Pharmacol., 1991, 28(2), 93-101.
94. Kim, R.; Tanabe, K.; Uchida, Y.; Emi, M.; Inoue, H.; Toge, T. Current status of the molecular mechanisms of anticancer druginduced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother. Pharmacol., 2002, 50(5), 343-352.
95. Makin, G.; Dive, C. Apoptosis and cancer chemotherapy. Trends Cell Biol., 2001, 11(11), S22-S26.
96. Tsuruo, T.; Naito, M.; Tomida, A.; Fujita, N.; Mashima, T.; Sakamoto, H.; Haga, N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci., 2003, 94(1), 15-21.
97. Makin, G.; Hickman, J.A. Apoptosis and cancer chemotherapy. Cell Tissue Res., 2000, 301(1), 143-152.
98. Bu, R.; Uddin, S.; Bavi, P.; Hussain, A.R.; Al-Dayel, F.; Ghourab, S.; Ahmed, M.; Al-Kuraya, K.S. HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma. Lab Invest., 2010, 91(1), 124-137.
99. Amaral, J.D.; Xavier, J.M.; Steer, C.J.; Rodrigues, C.M. The role of p53 in apoptosis. Discov. Med., 2010, 9(45), 145-152.
100. Chipuk, J.E.; Green, D.R. Dissecting p53-dependent apoptosis. Cell Death Differ., 2006, 13(6), 994-1002.
101. Hemann, M.T.; Lowe, S.W. The p53-Bcl-2 connection. Cell Death Differ., 2006, 13(8), 1256-1259.
102. Petros, A.M.; Gunasekera, A.; Xu, N.; Olejniczak, E.T.; Fesik, S.W. Defining the p53 DNA-binding domain/Bcl-x(L)-binding interface using NMR. FEBS Lett., 2004, 559(1-3), 171-174.
103. Tomita, Y.; Marchenko, N.; Erster, S.; Nemajerova, A.; Dehner, A.; Klein, C.; Pan, H.; Kessler, H.; Pancoska, P.; Moll, U.M. WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J. Biol. Chem., 2006, 281(13), 8600-8606.
104. Oltvai, Z.N.; Milliman, C.L.; Korsmeyer, S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 1993, 74(4), 609-619.
105. Brunelle, J.K.; Letai, A. Control of mitochondrial apoptosis by the Bcl-2 family. J. Cell. Sci., 2009, 122(Pt 4), 437-441.
106. Degli Esposti, M.; Dive, C. Mitochondrial membrane permeabilisation by Bax/Bak. Biochem. Biophys. Res. Commun., 2003, 304(3), 455-461.
107. Nagata, S. Apoptotic DNA fragmentation. Exp. Cell. Res., 2000, 256(1), 12-18.
108. Pallis, M.; Russell, N. P-glycoprotein plays a drug-effluxindependent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelinceramide apoptotic pathway. Blood, 2000, 95(9), 2897-2904.
109. Ruefli, A.A., Johnstone, R. W A role for P-glycoprotein in regulating cell growth and survival. Clinic. Applied Immunol. Rev., 2003, 4(1), 31-41.
110. Hoffman, M.M.; Wei, L.Y.; Roepe, P.D. Are altered pHi and membrane potential in hu MDR 1 transfectants sufficient to cause MDR protein-mediated multidrug resistance? J. Gen. Physiol., 1996, 108(4), 295-313.
111. Bear, C.E. Drugs transported by P-glycoprotein inhibit a 40 pS outwardly rectifying chloride channel. Biochem. Biophys. Res. Commun., 1994, 200(1), 513-521.
112. Idriss, H.T.; Hannun, Y.A.; Boulpaep, E.; Basavappa, S. Regulation of volume-activated chloride channels by Pglycoprotein: phosphorylation has the final say! J. Physiol., 2000, 524 Pt 3(629-636.
113. Sulova, Z.; Orlicky, J.; Fiala, R.; Dovinova, I.; Uhrik, B.; Seres, M.; Gibalova, L.; Breier, A. Expression of P-glycoprotein in L1210 cells is linked with rise in sensitivity to Ca2+. Biochem. Biophys. Res. Commun., 2005, 335(3), 777-784.
114. Sulova, Z.; Seres, M.; Barancik, M.; Gibalova, L.; Uhrik, B.; Polekova, L.; Breier, A. Does any relationship exist between Pglycoprotein-mediated multidrug resistance and intracellular calcium homeostasis. Gen. Physiol. Biophys, 2009, 28 (Focused issue), F89-95.
115. Olofsson, M.H.; Havelka, A.M.; Brnjic, S.; Shoshan, M.C.; Linder, S. Charting calcium-regulated apoptosis pathways using chemical biology: role of calmodulin kinase II. BMC Chem. Biol., 2008, 8(2), 1-10.
116. Smaili, S.; Hirata, H.; Ureshino, R.; Monteforte, P.T.; Morales, A.P.; Muler, M.L.; Terashima, J.; Oseki, K.; Rosenstock, T.R.; Lopes, G.S.; Bincoletto, C. Calcium and cell death signaling in neurodegeneration and aging. An. Acad. Bras.Cienc., 2009, 81(3), 467-475.
117. Tainton, K.M.; Smyth, M.J.; Jackson, J.T.; Tanner, J.E.; Cerruti, L.; Jane, S.M.; Darcy, P.K.; Johnstone, R.W. Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ., 2004, 11(9), 1028-1037.
118. Gibalova, L.; Sedlak, J.; Labudova, M.; Barancik, M.; Rehakova, A.; Breier, A.; Sulova, Z. Multidrug resistant P-glycoprotein positive L1210/VCR cells are also cross-resistant to cisplatin via a mechanism distinct from P-glycoprotein-mediated drug efflux activity. Gen. Physiol. Biophys., 2009, 28(4), 391-403.
119. Gibalova, L.; Seres, M.; Rusnak, A.; Ditte, P.; Labudova, M.; Uhrik, B.; Pastorek, J.; Sedlak, J.; Breier, A.; Sulova, Z. Pglycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation. Toxicol. In Vitro, 2012, 26(3), 435-444.
120. Kirsch, D.G.; Doseff, A.; Chau, B.N.; Lim, D.S.; de Souza-Pinto, N.C.; Hansford, R.; Kastan, M.B.; Lazebnik, Y.A.; Hardwick, J.M. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J. Biol. Chem., 1999, 274(30), 21155-21161.
121. Maeda, T.; Hobbs, R.M.; Merghoub, T.; Guernah, I.; Zelent, A.; Cordon-Cardo, C.; Teruya-Feldstein, J.; Pandolfi, P.P. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature, 2005, 433(7023), 278-285.
122. Maeda, T.; Hobbs, R.M.; Pandolfi, P.P. The transcription factor Pokemon: a new key player in cancer pathogenesis. Cancer Res., 2005, 65(19), 8575-8578.
123. He, S.; Liu, F.; Xie, Z.; Zu, X.; Xu, W.; Jiang, Y. PGlycoprotein/ MDR1 Regulates Pokemon Gene Transcription Through p53 Expression in Human Breast Cancer Cells. Int. J. Mol. Sci., 2010, 11(9), 3309-3051.
124. Gan, L.; Wang, J.; Xu, H.; Yang, X. Resistance to docetaxelinduced apoptosis in prostate cancer cells by p38/p53/p21 signaling. Prostate, 2011, 71(11), 1158-1166.
125. Seo, S.B.; Hur, J.G.; Kim, M.J.; Lee, J.W.; Kim, H.B.; Bae, J.H.; Kim, D.W.; Kang, C.D.; Kim, S.H. TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3beta pathway and activation of caspases. Mol. Cancer, 2010, 9(199).
126. Tournier, C.; Hess, P.; Yang, D.D.; Xu, J.; Turner, T.K.; Nimnual, A.; Bar-Sagi, D.; Jones, S.N.; Flavell, R.A.; Davis, R.J. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science, 2000, 288(5467), 870-874.
127. Wang, L.G.; Liu, X.M.; Kreis, W.; Budman, D.R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother. Pharmacol., 1999, 44(5), 355-361.
128. Zambon, A.C.; Wilderman, A.; Ho, A.; Insel, P.A. Increased Expression of the Pro-apoptotic Protein BIM, a Mechanism for cAMP/Protein Kinase A (PKA)-induced Apoptosis of Immature T Cells. J. Biol. Chem., 2011, 286(38), 33260-33267.
129. He, X.; Wang, J.; Guo, Z.; Liu, Q.; Chen, T.; Wang, X.; Cao, X. Requirement for ERK activation in sinomenine-induced apoptosis of macrophages. Immunol. Lett., 2005, 98(1), 91-96.
130. Kim, E.K.; Choi, E.J. Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta, 2010, 1802(4), 396-405.
131. Pepper, C.; Thomas, A.; Hoy, T.; Milligan, D.; Bentley, P.; Fegan, C. The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. Blood, 2003, 101(7), 2454-2460.
132. Wada, T.; Penninger, J.M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene, 2004, 23(16), 2838-2849.
133. Xia, Z.; Dickens, M.; Raingeaud, J.; Davis, R.J.; Greenberg, M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science, 1995, 270(5240), 1326-1331.
134. Barancik, M.; Bohacova, V.; Kvackajova, J.; Hudecova, S.; Krizanova, O.; Breier, A. SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoproteinmediated multidrug resistance. Eur. J. Pharm. Sci., 2001, 14(1), 29-36.
135. Guo, X.; Ma, N.; Wang, J.; Song, J.; Bu, X.; Cheng, Y.; Sun, K.; Xiong, H.; Jiang, G.; Zhang, B.; Wu, M.; Wei, L. Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer, 2008, 8(375.
136. Katayama, K.; Yoshioka, S.; Tsukahara, S.; Mitsuhashi, J.; Sugimoto, Y. Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther., 2007, 6(7), 2092-2102.
137. Kisucka, J.; Barancik, M.; Bohacova, V.; Breier, A. Reversal effect of specific inhibitors of extracellular-signal regulated protein kinase pathway on P-glycoprotein mediated vincristine resistance of L1210 cells. Gen. Physiol. Biophys., 2001, 20(4), 439-444.
138. Li, C.; Fan, S.; Owonikoko, T.K.; Khuri, F.R.; Sun, S.Y.; Li, R. Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway. Oncogene, 2011, 30(35), 3802-3812.
139. Ley, R.; Hadfield, K.; Howes, E.; Cook, S.J. Identification of a DEF-type docking domain for extracellular signal-regulated kinases 1/2 that directs phosphorylation and turnover of the BH3-only protein BimEL. J. Biol. Chem., 2005, 280(18), 17657-17663.
140. Muzio, M.; Apollonio, B.; Scielzo, C.; Frenquelli, M.; Vandoni, I.; Boussiotis, V.; Caligaris-Cappio, F.; Ghia, P. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood, 2008, 112(1), 188-195.
141. Zhuang, S.; Schnellmann, R.G. A death-promoting role for extracellular signal-regulated kinase. J. Pharmacol. Exp. Ther., 2006, 319(3), 991-997.
142. Brozovic, A.; Osmak, M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett., 2007, 251(1), 1-16.
143. Kang, Y.H.; Lee, S.J. Role of p38 MAPK and JNK in enhanced cervical cancer cell killing by the combination of arsenic trioxide and ionizing radiation. Oncol. Rep., 2008, 20(3), 637-643.
144. She, Q.B.; Chen, N.; Bode, A.M.; Flavell, R.A.; Dong, Z. Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res., 2002, 62(5), 1343-1348.
145. Shibata, W.; Maeda, S.; Hikiba, Y.; Yanai, A.; Sakamoto, K.; Nakagawa, H.; Ogura, K.; Karin, M.; Omata, M. c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice. Cancer Res., 2008, 68(13), 5031-5039.
146. Wagner, E.F.; Nebreda, A.R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer, 2009, 9(8), 537-549.
147. Nishina, H.; Wada, T.; Katada, T. Physiological roles of SAPK/JNK signaling pathway. J Biochem, 2004, 136(2), 123-126.
148. Sunayama, J.; Tsuruta, F.; Masuyama, N.; Gotoh, Y. JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. J. Cell. Biol., 2005, 170(2), 295-304.
149. Chiarini, F.; Del Sole, M.; Mongiorgi, S.; Gaboardi, G.C.; Cappellini, A.; Mantovani, I.; Follo, M.Y.; McCubrey, J.A.; Martelli, A.M. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia, 2008, 22(6), 1106-1116.
150. Tang, P.M.; Zhang, D.M.; Xuan, N.H.; Tsui, S.K.; Waye, M.M.; Kong, S.K.; Fong, W.P.; Fung, K.P. Photodynamic therapy inhibits P-glycoprotein mediated multidrug resistance via JNK activation in human hepatocellular carcinoma using the photosensitizer pheophorbide a. Mol. Cancer, 2009, 8(56.
151. Ambrosino, C.; Nebreda, A.R. Cell cycle regulation by p38 MAP kinases. Biol. Cell, 2001, 93(1-2), 47-51.
152. Han, J.; Sun, P. The pathways to tumor suppression via route p38. Trends Biochem. Sci., 2007, 32(8), 364-371.
153. Deacon, K.; Mistry, P.; Chernoff, J.; Blank, J.L.; Patel, R. p38 Mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest. Mol. Biol. Cell, 2003, 14(5), 2071-2087.
154. Heinrichsdorff, J.; Luedde, T.; Perdiguero, E.; Nebreda, A.R.; Pasparakis, M. p38 alpha MAPK inhibits JNK activation and collaborates with IkappaB kinase 2 to prevent endotoxin-induced liver failure. EMBO Rep, 2008, 9(10), 1048-1054.
155. Losa, J.H.; Parada Cobo, C.; Viniegra, J.G.; Sanchez-Arevalo Lobo, V.J.; Ramon y Cajal, S.; Sanchez-Prieto, R. Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene, 2003, 22(26), 3998-4006.
156. Bellacosa, A.; Kumar, C.C.; Di Cristofano, A.; Testa, J.R. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv. Cancer Res., 2005, 94(29)-86.
157. Lee, J.T., Jr.; Steelman, L.S.; McCubrey, J.A. Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res., 2004, 64(22), 8397-8404.
158. Rychahou, P.G.; Jackson, L.N.; Silva, S.R.; Rajaraman, S.; Evers, B.M. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. An.n Surg., 2006, 243(6), 833-842; discussion 843-834.
159. Barancik, M.; Bohacova, V.; Sedlak, J.; Sulova, Z.; Breier, A. LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. Eur. J. Pharm. Sci., 2006, 29(5), 426-434.
160. Cordo Russo, R.I.; Garcia, M.G.; Alaniz, L.; Blanco, G.; Alvarez, E.; Hajos, S.E. Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway. Int. J. Cancer, 2008, 122(5), 1012-1018.
161. Garcia, M.G.; Alaniz, L.D.; Cordo Russo, R.I.; Alvarez, E.; Hajos, S.E. PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines. Leuk. Res., 2009, 33(2), 288-296.
162. Chu, W.C.; Hong, W.F.; Huang, M.C.; Chen, F.Y.; Lin, S.C.; Liao, P.J.; Su, J.G. 1-Nitropyrene stabilizes the mRNA of cytochrome P450 1a1, a carcinogen-metabolizing enzyme, via the Akt pathway. Chem. Res. Toxicol., 2009, 22(12), 1938-1947.
163. Choi, H.K.; Yang, J.W.; Roh, S.H.; Han, C.Y.; Kang, K.W. Induction of multidrug resistance associated protein 2 in tamoxifenresistant breast cancer cells. Endocr, Relat, Cancer, 2007, 14(2), 293-303.
164. Zhou, J.; Liu, M.; Zhai, Y.; Xie, W. The antiapoptotic role of pregnane X receptor in human colon cancer cells. Mol. Endocrinol., 2008, 22(4), 868-880.
165. Zucchini, N.; de Sousa, G.; Bailly-Maitre, B.; Gugenheim, J.; Bars, R.; Lemaire, G.; Rahmani, R. Regulation of Bcl-2 and Bcl-xL antiapoptotic protein expression by nuclear receptor PXR in primary cultures of human and rat hepatocytes. Biochim. Biophys. Acta, 2005, 1745(1), 48-58.
166. Kodama, S.; Negishi, M. Pregnane X receptor PXR activates the GADD45beta gene, eliciting the p38 MAPK signal and cell migration. J. Biol. Chem., 2011, 286(5), 3570-3578.
167. Avendano, C.; Perez, J.M.; Blanco Mdel, M.; de la Fuente, J.A.; Manzanaro, S.; Vicent, M.J.; Martin, M.J.; Salvador-Tormo, N.; Menendez, J.C. Synthesis and structure-activity relationships of 1,5-diazaanthraquinones as antitumour compounds. Bioorg. Med. Chem. Lett., 2004, 14(15), 3929-3932.
168. Barancik, M.; Bohacova, V.; Gibalova, L.; Sedlak, J.; Sulova, Z.; Breier, A. Potentiation of anticancer drugs: effects of pentoxifylline on neoplastic cells. Int. J. Mol. Sci., 2012, 13(1), 369-382.
169. Barancik, M.; Polekova, L.; Mrazova, T.; Breier, A.; Stankovicova, T.; Slezak, J. Reversal effects of several Ca(2+)-entry blockers, neuroleptics and local anaesthetics on P-glycoprotein-mediated vincristine resistance of L1210/VCR mouse leukaemic cell line. Drugs Exp. Clin. Res., 1994, 20(1), 13-18.
170. Breier, A.; Barancik, M.; Stefankova, Z.; Uhrik, B.; Tribulova, N. Effect of pentoxifylline on P-glycoprotein mediated vincristine resistance of L1210 mouse leukemic cell line. Neoplasma, 1994, 41(5), 297-303.
171. Breier, A.; Drobna, Z.; Barancik, M. Direct interaction between verapamil and doxorubicin causes the lack of reversal effect of verapamil on P-glycoprotein mediated resistance to doxorubicin in vitro using L1210/VCR cells. Neoplasma, 1998, 45(4), 248-253.
172. Conseil, G.; Baubichon-Cortay, H.; Dayan, G.; Jault, J.M.; Barron, D.; Di Pietro, A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP-and steroid-binding sites on mouse P-glycoprotein. Proc. Natl. Acad. Sci. U. S. A., 1998, 95(17), 9831-9836.
173. Docolomansky, P.; Bohacova, V.; Barancik, M.; Breier, A. Why the xanthine derivatives are used to study of P-glycoproteinmediated multidrug resistance in L1210/VCR line cells. Gen. Physiol. Biophys., 2010, 29(3), 215-221.
174. Drobna, Z.; Stein, U.; Walther, W.; Barancik, M.; Breier, A. Pentoxifylline influences drug transport activity of P-glycoprotein and decreases mdrl gene expression in multidrug resistant mouse leukemic L1210/VCR cells. Gen. Physiol. Biophys., 2002, 21(1), 103-109.
175. Garrigos, M.; Mir, L.M.; Orlowski, S. Competitive and noncompetitive inhibition of the multidrug-resistance-associated Pglycoprotein ATPase--further experimental evidence for a multisite model. Eur. J. Biochem., 1997, 244(2), 664-673.
176. Kellen, J.A. The reversal of multidrug resistance: an update. J. Exp. Ther. Oncol., 2003, 3(1), 5-13.
177. Kupsakova, I.; Rybar, A.; Docolomansky, P.; Drobna, Z.; Stein, U.; Walther, W.; Barancik, M.; Breier, A. Reversal of P-glycoprotein mediated vincristine resistance of L1210/VCR cells by analogues of pentoxifylline. A QSAR study. Eur. J. Pharm. Sci., 2004, 21(2-3), 283-293.
178. Lehne, G. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr. Drug Targets, 2000, 1(1), 85-99.
179. Wiese, M.; Pajeva, I.K. Structure-activity relationships of multidrug resistance reversers. Curr. Med. Chem., 2001, 8(6), 685-713.
180. Pilarski, L.M.; Yatscoff, R.W.; Murphy, G.F.; Belch, A.R. Drug resistance in multiple myeloma: cyclosporin A analogues and their metabolites as potential chemosensitizers. Leukemia, 1998, 12(4), 505-509.
181. Biscardi, M.; Teodori, E.; Caporale, R.; Budriesi, R.; Balestri, F.; Scappini, B.; Gavazzi, S.; Grossi, A. Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity. Leuk. Res., 2006, 30(1), 1-8.
182. al-Shawi, M.K.; Urbatsch, I.L.; Senior, A.E. Covalent inhibitors of P-glycoprotein ATPase activity. J. Biol. Chem., 1994, 269(12), 8986-8992.
183. Loo, T.W.; Clarke, D.M. Covalent modification of human Pglycoprotein mutants containing a single cysteine in either nucleotide-binding fold abolishes drug-stimulated ATPase activity. J. Biol. Chem., 1995, 270(39), 22957-22961.
184. Urbatsch, I.L.; al-Shawi, M.K.; Senior, A.E. Characterization of the ATPase activity of purified Chinese hamster P-glycoprotein. Biochemistry, 1994, 33(23), 7069-7076.
185. Hu, K.; Morris, M.E. Effects of benzyl-, phenethyl-, and alphanaphthyl isothiocyanates on P-glycoprotein-and MRP1-mediated transport. J. Pharm. Sci., 2004, 93(7), 1901-1911.
186. Conseil, G.; Perez-Victoria, J.M.; Jault, J.M.; Gamarro, F.; Goffeau, A.; Hofmann, J.; Di Pietro, A. Protein kinase C effectors bind to multidrug ABC transporters and inhibit their activity. Biochemistry, 2001, 40(8), 2564-2571.
187. Gekeler, V.; Boer, R.; Uberall, F.; Ise, W.; Schubert, C.; Utz, I.; Hofmann, J.; Sanders, K.H.; Schachtele, C.; Klemm, K.; Grunicke, H. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance. Br. J. Cancer, 1996, 74(6), 897-905.
188. Li, X.; Li, J.P.; Yuan, H.Y.; Gao, X.; Qu, X.J.; Xu, W.F.; Tang, W. Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms. Methods Find Exp. Clin. Pharmacol., 2007, 29(9), 607-617.
189. Aszalos, A. Role of ATP-binding cassette (ABC) transporters in interactions between natural products and drugs. Curr. Drug Metab., 2008, 9(10), 1010-1018.
190. Nabekura, T. Overcoming multidrug resistance in human cancer cells by natural compounds. Toxins (Basel), 2010, 2(6), 1207-1224.
191. Nabekura, T.; Yamaki, T.; Ueno, K.; Kitagawa, S. Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals. Cancer Chemother. Pharmacol., 2008, 62(5), 867-873.
192. Ekins, S.; Chang, C.; Mani, S.; Krasowski, M.D.; Reschly, E.J.; Iyer, M.; Kholodovych, V.; Ai, N.; Welsh, W.J.; Sinz, M.; Swaan, P.W.; Patel, R.; Bachmann, K. Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol. Pharmacol., 2007, 72(3), 592-603.
193. Li, L.; Chen, T.; Stanton, J.D.; Sueyoshi, T.; Negishi, M.; Wang, H. The peripheral benzodiazepine receptor ligand 1-(2-chlorophenylmethylpropyl)-3-isoquinoline-carboxamide is a novel antagonist of human constitutive androstane receptor. Mol. Pharmacol., 2008, 74(2), 443-453.
194. Stedman, C.A.; Liddle, C.; Coulter, S.A.; Sonoda, J.; Alvarez, J.G.; Moore, D.D.; Evans, R.M.; Downes, M. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc. Natl. Acad. Sci. U. S. A., 2005, 102(6), 2063-2068.
195. Suttana, W.; Mankhetkorn, S.; Poompimon, W.; Palagani, A.; Zhokhov, S.; Gerlo, S.; Haegeman, G.; Berghe, W.V. Differential chemosensitization of P-glycoprotein overexpressing K562/Adr cells by withaferin A and Siamois polyphenols. Mol. Cancer, 2010, 9(99).
196. Choi, B.H.; Kim, C.G.; Lim, Y.; Shin, S.Y.; Lee, Y.H. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett., 2008, 259(1), 111-118.
197. Lu, X.J.; Xu, W.L.; Luo, W.J.; Wang, F.C.; Chen, Q.Y. [Effect of tetrandrine on the doxorubicin-induced expression of mdr1 gene in K562 cells]. Zhonghua Xue Ye Xue Za Zhi, 2008, 29(7), 468-471.
198. Stefankova, Z.; Barancik, M.; Breier, A. Overcoming of Pglycoprotein mediated vincristine resistance of L1210/VCR mouse leukemic cells could be induced by pentoxifyline but not by theophylline and caffeine. Neoplasma, 1996, 43(1), 11-15.
199. Docolomansky, P.; Fialova, I.; Barancik, M.; Rybar, A.; Breier, A. Prolongation of pentoxifylline aliphatic side chain positively affects the reversal of P-glycoprotein-mediated multidrug resistance in L1210/VCR line cells. Gen. Physiol. Biophys., 2005, 24(4), 461-466.
200. Bravo-Cuellar, A.; Ortiz-Lazareno, P.C.; Lerma-Diaz, J.M.; Dominguez-Rodriguez, J.R.; Jave-Suarez, L.F.; Aguilar-Lemarroy, A.; del Toro-Arreola, S.; de Celis-Carrillo, R.; Sahagun-Flores, J.E.; de Alba-Garcia, J.E.; Hernandez-Flores, G. Sensitization of cervix cancer cells to Adriamycin by Pentoxifylline induces an increase in apoptosis and decrease senescence. Mol. Cancer, 2010, 9(114).
201. Hernandez-Flores, G.; Ortiz-Lazareno, P.C.; Lerma-Diaz, J.M.; Dominguez-Rodriguez, J.R.; Jave-Suarez, L.F.; Aguilar-Lemarroy Adel, C.; de Celis-Carrillo, R.; del Toro-Arreola, S.; Castellanos-Esparza, Y.C.; Bravo-Cuellar, A. Pentoxifylline sensitizes human cervical tumor cells to cisplatin-induced apoptosis by suppressing NF-kappa B and decreased cell senescence. BMC Cancer, 2011, 11(483.
202. Germann, U.A.; Chambers, T.C.; Ambudkar, S.V.; Pastan, I.; Gottesman, M.M. Effects of phosphorylation of P-glycoprotein on multidrug resistance. J. Bioenerg. Biomembr., 1995, 27(1), 53-61.
203. Barancik, M.; Stefankova, Z.; Breier, A. Effect of phorbol myristate acetate (PMA) on P-glycoprotein mediated vincristine resistance of L1210 cells. Gen. Physiol. Biophys., 1995, 14(2), 171-175.
204. Chaudhary, P.M.; Roninson, I.B. Activation of MDR1 (Pglycoprotein) gene expression in human cells by protein kinase C agonists. Oncol. Res., 1992, 4(7), 281-290.
205. Osborn, M.T.; Berry, A.; Ruberu, M.S.; Ning, B.; Bell, L.M.; Chambers, T.C. Phorbol ester induced MDR1 expression in K562 cells occurs independently of mitogen-activated protein kinase signaling pathways. Oncogene, 1999, 18(42), 5756-5764.
206. Goodfellow, H.R.; Sardini, A.; Ruetz, S.; Callaghan, R.; Gros, P.; McNaughton, P.A.; Higgins, C.F. Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. J. Biol. Chem., 1996, 271(23), 13668-13674.
207. Takeda, K.; Naguro, I.; Nishitoh, H.; Matsuzawa, A.; Ichijo, H. Apoptosis signaling kinases: from stress response to health outcomes. Antioxid. Redox. Signal, 2011, 15(3), 719-761.
208. Denkert, C.; Siegert, A.; Leclere, A.; Turzynski, A.; Hauptmann, S. An inhibitor of stress-activated MAP-kinases reduces invasion and MMP-2 expression of malignant melanoma cells. Clin. Exp. Metastasis, 2002, 19(1), 79-85.
209. Meyers, M.B. Protein phosphorylation in multidrug resistant Chinese hamster cells. Cancer Commun., 1989, 1(4), 233-241.
210. Sorokin, A. Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr. Pharm. Des., 2004, 10(6), 647-657.
211. Awara, W.M.; El-Sisi, A.E.; El-Sayad, M.E.; Goda, A.E. The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin? Pharmacol. Res., 2004, 50(5), 487-498.
212. Kim, S.K.; Lim, S.Y.; Wang, K.C.; Kim, Y.Y.; Chi, J.G.; Choi, Y.L.; Shin, H.J.; Cho, B.K. Overexpression of cyclooxygenase-2 in childhood ependymomas: role of COX-2 inhibitor in growth and multi-drug resistance in vitro. Oncol. Rep., 2004, 12(2), 403-409.
213. Zrieki, A.; Farinotti, R.; Buyse, M. Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycoprotein upregulation in vitro and in vivo. Eur. J. Pharmacol., 2010, 636(1-3), 189-197.
214. Comerford, K.M.; Wallace, T.J.; Karhausen, J.; Louis, N.A.; Montalto, M.C.; Colgan, S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res., 2002, 62(12), 3387-3394.
215. Wartenberg, M.; Gronczynska, S.; Bekhite, M.M.; Saric, T.; Niedermeier, W.; Hescheler, J.; Sauer, H. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular prostate tumor spheroids by hyperthermia and reactive oxygen species. Int. J. Cancer, 2005, 113(2), 229-240.
216. Wartenberg, M.; Ling, F.C.; Muschen, M.; Klein, F.; Acker, H.; Gassmann, M.; Petrat, K.; Putz, V.; Hescheler, J.; Sauer, H. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J., 2003, 17(3), 503-505.
217. Legendre, C.; Hori, T.; Loyer, P.; Aninat, C.; Ishida, S.; Glaise, D.; Lucas-Clerc, C.; Boudjema, K.; Guguen-Guillouzo, C.; Corlu, A.; Morel, F. Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1alpha involvement in CYP3A4 repression. Eur. J. Cancer, 2009, 45(16), 2882-2892.
218. Pastorekova, S.; Ratcliffe, P.J.; Pastorek, J. Molecular mechanisms of carbonic anhydrase IX-mediated pH regulation under hypoxia. BJU Int., 2008, 101 Suppl 4, 8-15.